Late Wednesday, the clinical-stage company said the FDA is unable to approve govorestat's new drug application for the treatment of classic galactosemia in its current form amid "deficiencies" in ...

It also significantly reduced plasma galactitol levels in adults and children with galactosemia. Additional studies provided strong efficacy and safety data across 185 classic galactosemia ...